AIMHIGH SIGNALRISK10-K

AIM has dramatically narrowed its strategic focus to solely pancreatic cancer while experiencing severe financial deterioration including a 640% decline in stockholders' equity to negative $9.8M.

The company has abandoned its diversified approach across multiple indications (ME/CFS, Post-COVID, antiviral programs) to bet everything on pancreatic cancer, creating dangerous concentration risk for a cash-strapped biotech. This strategic pivot, combined with deteriorating financials and increased debt burden, suggests the company may be in survival mode and facing potential going concern issues.

Comparing 2026-03-27 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

AIM's financial position has severely deteriorated with stockholders' equity plummeting 640% to negative $9.8M and total liabilities surging 57% to $15.6M, while revenue collapsed 48% and accounts receivable nearly disappeared. Despite reducing R&D expenses by 37% and improving operating losses by 41%, the company increased debt 60% and interest expenses rose 39%, indicating heavy reliance on external financing. The overall picture shows a company burning through resources while desperately trying to extend its runway through cost cuts and debt financing.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-640%
-$1.3M→-$9.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Accounts Receivable
Balance Sheet
-99.4%
$1.2M→$7K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-79.1%
$86K→$18K

Capex reduced 79.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+75.5%
$1.7M→$3.0M

Cash position surged 75.5% — strong cash generation or capital raise providing significant financial cushion.

Total Debt
Balance Sheet
+59.5%
$2.8M→$4.5M

Debt increased 59.5% — substantial leverage increase; assess whether deployed for growth or covering losses.

Total Liabilities
Balance Sheet
+56.7%
$9.9M→$15.6M

Liabilities grew 56.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
-48.2%
$170K→$88K

Revenue declined 48.2% — significant demand weakness or market share loss warrants investigation.

Operating Income
P&L
+41%
-$19.8M→-$11.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
+38.8%
$585K→$812K

Interest expense surged 38.8% — significant debt increase or rising rates materially impacting earnings.

R&D Expense
P&L
-36.7%
$6.2M→$3.9M

R&D spending cut 36.7% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-27
ADDED
and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies.
The Company s research and development of Ampligen has included a variety of diseases and health matters: Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer.
Based on clinical success as to safety and efficacy in our pancreatic cancer Early Access Program and an ongoing Phase 2 trial, AIM has made the business decision to focus its efforts on the development of Ampligen for the treatment of late-stage pancreatic cancer, as we believe that of all the opportunities a wide-spectrum therapeutic such as Ampligen has pancreatic cancer treatment is the path that will potentially lead to the most lucrative outcome.
While Ampligen showed positive safety and efficacy in trials involving other solid tumor types, we believe that pancreatic cancer presents the best business opportunity.
Pancreatic cancer killed more than 100,000 people in the American and European Union markets and more than 450,000 people worldwide as recently as 2022.
+7 more — sign up free →
REMOVED
and its subsidiaries (collectively, AIM , Company , we or us ) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders and to treat cancers for which there are currently inadequate or unmet therapies.
The Company is currently proceeding primarily in four areas: Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer.
The Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation.
The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency ( EMA ), which trials support a potential future NDA.
However, AIM s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →